4.5 Article Proceedings Paper

The right drug and the right dose

Journal

JOURNAL OF HYPERTENSION
Volume 21, Issue -, Pages S31-S36

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00004872-200305002-00006

Keywords

angiotensin-converting enzyme inhibitor; alpha-adrenoceptor blocker; angiotensin-II receptor antagonist; antihypertensive; beta-blocker; blood pressure; calcium channel blocker; diuretic

Ask authors/readers for more resources

The goal of antihypertensive treatment is to reduce both blood pressure and other risk factors for cardiovascular disease. There are currently six major classes of antihypertensive drugs that are available for the initial lowering and maintenance of blood pressure, including beta-blockers, alpha-adrenoceptor blockers, calcium channel blockers, diuretics, angiotensin-converting enzyme inhibitors and angiotensin-II receptor antagonists. All these classes of anti hypertensive drugs are equally effective in reducing high blood pressure. To select the right antihypertensive drug, characteristics other than efficacy should be used to distinguish the different classes. According to the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the selection of initial antihypertensive drug should consider patient risk-factor profile and co-morbidity, as well as the safety and tolerability profile of the drug. When these factors are considered, an effective and well-tolerated drug regimen can be tailored to an individual patient. An initial drug regimen should consist of a low dose of a long-acting, once-daily drug that is titrated upward if blood pressure is not adequately controlled. Low-dose combinations of two antihypertensive drugs may also be considered. Results from comparative studies with different classes of antihypertensive drugs suggest that different populations of patients, such as those with diabetes, left-ventricular dysfunction, or lipid disorders, may benefit from taking different anti hypertensive drugs. J Hypertens 21 (suppl 2): S31-S36 (C) 2003 Lippincott Williams Wilkins.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available